Free US stock earnings analysis and guidance reviews to understand company fundamentals and future prospects. Our earnings season coverage includes detailed analysis of financial results and what they mean for your investment thesis.
On April 21, 2026, Merck (MRK) announced that U.S. FDA granted priority review to two supplemental biologics license applications (sBLAs) for its Keytruda (both intravenous and subcutaneous formulations) in combination with Pfizer’s antibody-drug conjugate (ADC) Padcev, for the treatment of cisplati
Pfizer Inc. (PFE) – Padcev Combination Therapy Receives FDA Priority Review for Expanded Bladder Cancer Indication - Partnership
PFE - Stock Analysis
4388 Comments
809 Likes
1
Monyka
Active Contributor
2 hours ago
I don’t understand but I feel included.
👍 179
Reply
2
Terrea
Engaged Reader
5 hours ago
This made sense in an alternate timeline.
👍 251
Reply
3
Quasha
Regular Reader
1 day ago
This feels like a secret but no one told me.
👍 227
Reply
4
Tomora
Daily Reader
1 day ago
Who else is trying to understand what’s happening?
👍 214
Reply
5
Vishak
Active Reader
2 days ago
Expert US stock fundamental screening criteria and quality metrics to identify companies with durable competitive advantages. Our fundamental analysis goes beyond simple ratios to understand the true drivers of long-term business value.
👍 59
Reply
© 2026 Market Analysis. All data is for informational purposes only.